AcuCort AB, a Swedish pharmaceutical company, has announced the successful launch of its innovative product, Zeqmelit®, in the Nordic countries. Initially introduced in Sweden, Norway, and Finland in September 2024, the product will make its way to Denmark by the summer of 2025. This strategic expansion is supported by a new order from Unimedic Pharma, AcuCort's Nordic distribution partner, valued at EUR 112,000.

According to Jonas Jönmark, CEO of AcuCort, the launch is progressing as anticipated for a new pharmaceutical product. Zeqmelit® is a rapidly dissolving oral film based on dexamethasone, designed for treating severe allergic reactions, croup in children, chemotherapy-induced nausea, and COVID-19 in patients needing supplemental oxygen.

The positive reception of Zeqmelit® in the Nordic market is expected to reflect favorably on AcuCort's financial performance in the second quarter of 2026. This aligns with the company's strategy to establish a strong foothold in the region, leveraging the innovative and user-friendly nature of Zeqmelit®.

Given the promising market response and the strategic positioning of Zeqmelit®, investors may find AcuCort a compelling prospect. However, considering the pharmaceutical industry's inherent risks and the need for continued market penetration, a hold recommendation is prudent for potential investors at this stage.